As VEGFR2 transcription was downregulated in tumor cells after morusin treatment, it seemed possible that the medication addressed the vascular endothelial growth factor (VEGF)/VEGFR2 signaling pathway, suggesting that morusin acted as an angiogenesis inhibitor (Gao et al., 2017). This evidence concerns the gene KDR and neoplasm.